Project Description

A/Prof. Lutz Krause

The University of Queensland

Genomic signatures predict response to cancer immunotherapy

Next generation sequencing & bioinformatics

Monday 2 July 2018

A/Prof. Lutz Krause applies computational and mathematical methods to understand genomic changes underlying disease. He undertook undergraduate studies in Computer Science and completed a PhD in Bioinformatics and Genome Research at Bielefeld University, Germany. During his graduate studies his primary research interests were in machine-learning, omics’ data anlaysis and artificial intelligence. In 2008 he joined the Nestlé Research Institute in Lausanne, Switzerland, where he studied the role of the gut microbiota in health and disease, particularly obesity and diabetes. In 2010 he was recruited to QIMR Berghofer to head the Bioinformatics team and in 2014 he joined the University of Queensland Diamantina Institute to pursue his research on the genetics and epigenetics of complex diseases, in particular cancer. In close collaboration with clinicians from the Princess Alexandra Hospital and Prince Charles Hospital, Lutz research aims at the identification of molecular biomarkers that help clinicians choosing the optimal treatment for individual patients with oesophageal adenocarcinoma or lung cancer.

Immunotherapy, a treatment using a person’s own immune system to fight cancer, has been one of the major breakthroughs in cancer therapy during the last years. However, while immunotherapy has shown to be highly effective in some patients, a high proportion of patients does not benefit from this treatment. To aid clinicians in the selection of optimal cancer therapies for individual patients there is an urgent need for predictive biomarkers of treatment response. This talk will introduce immunogenomics and discuss genomic biomarkers that can inform who is likely going to respond to immunotherapy.

Not available.